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Relationship Between Symptoms and Health-Related
Quality of Life in Patients Treated for Hypertension
Steven R. Erickson, Pharm.D., Brent C. Williams, M.D., M.P.H., and Larry D. Gruppen, Ph.D.
Study Objective. To determine the relationship between symptoms and
health-related quality of life (HRQOL) in patients receiving drug therapy
for hypertension.
Design. Cross-sectional survey.
Setting. Outpatient general medicine and university-based hypertension
clinics.
Patients. All patients prescribed one or more antihypertensive drugs seen
during a 6-month period in the clinics.
Intervention. Data were obtained from a mailed questionnaire and medical
records.
Measurements and Main Results. Symptoms were measured by a symptom
count and total symptom distress.  Two scores derived from the Short
Form-36 (SF-36)—the Physical Component Summary (PCS) and the
Mental Component Summary (MCS)—were used to assess HRQOL.
Responses were received from 125 of 220 patients (56.8%).  Mean ± SD
values were 8.8 ± 7.8 for symptom count, 31.6 ± 46.2 for total symptom
distress, 48.7 ± 9.3 for PCS, and 51.6 ± 10.1 for MCS.  Higher symptom
counts and symptom distress scores were strongly associated with lower
HRQOL scores in multivariate models, with standardized coefficients from
-0.62 to -0.41.  These were greater in magnitude than any other predictor,
including demographic information (age, sex, race, education level,
income), disease  variables (blood pressure, years of hypertension), and
drug treatment (number of antihypertensive drugs and duration of
regimen).  Model-adjusted R2 values were 0.22–0.41.
Conclusion. Symptoms have a greater impact on HRQOL than patient
characteristics, blood pressure, or drug-related factors.  Among patients
receiving drug therapy for hypertension, detailed review of symptoms may
yield important information for assessing and improving HRQOL.
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Patients with hypertension frequently report
symptoms that are similar to those reported by
patients without the diagnosis.1 Although
hypertension is often thought to be asympto-
matic, cognitive changes, mood alterations, and
general symptoms, such as dizziness and
headache attributable to hypertension, have been
described.2–7 Drugs used for the treatment of
hypertension also may cause symptoms, some of
which are specific to a particular drug, whereas
others are similar to symptoms described or
attributed to the disease of hypertension.8
Health-related quality of life (HRQOL) may be
influenced by symptoms, whether these are
derived from disease or treatment.  The term
HRQOL refers to the physical, emotional, and
social impact of disease and treatments9, 10 and is
distinct from physiologic measures of disease.9–12
The HRQOL of patients with hypertension may
be influenced by blood pressure, adverse effects
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of drugs used to treat hypertension, or other
factors, such as the labeling effect, or beliefs and
attitudes about illness and treatment.  At issue is
the determination of which variable or set of
variables has the greatest influence on HRQOL.
The relationships between patient, disease,
treatment variables, symptoms, and HRQOL were
described by a model published in 1995.13 This
model proposes that physiologic changes due to
illness or treatment lead to symptoms, which in
turn influences functional status or HRQOL.
These relationships are influenced by patient and
environmental variables that may affect patient
perception of symptoms and changes in HRQOL.
This general model can be applied to data from
clinical studies to ascertain the strength of
relationships between HRQOL and patient,
disease, and treatment variables.
We sought to determine the relationship
between symptoms and HRQOL in patients
receiving drug therapy for hypertension.  Our
population-based study used the published
model13 as a framework to identify and rank the
relationships between patient, disease, and
treatment variables and HRQOL.  We hypothesized
that those patients who report the most symptoms
or the most distress associated with symptoms
would have lowest HRQOL scores, independent
of blood pressure and other variables related to
patient or disease characteristics.
Methods
Study Setting and Patient Population
This study was a cross-sectional survey of
patients who attended either an outpatient
general medicine clinic or a university-based
hypertension clinic. All patients had a
documented diagnosis of hypertension and were
prescribed one or more antihypertensive drugs.
Patients were identified by a search of the billing
database for the internal medicine and
hypertension clinics for encounters with the
International Classification of Diseases, Ninth
Revision, diagnosis code for essential hypertension.
The database was searched for all patients who
had appointments at the clinics from July–December
1996.  The medical records of the identified patients
were reviewed to identify those meeting the study
criteria.
Age above 30 years was a criterion for inclusion.
Patients were excluded if they had other symp-
tomatic chronic disease states, such as pulmonary
disease (asthma or chronic obstructive pulmonary
diseases), inflammatory rheumatic diseases,
chronic heart failure (documented New York
Heart Association functional classes III or IV),
chronic pain syndromes, neurologic disorders or
deficits, ischemic heart disease, or diabetes
mellitus.  Patients also were excluded if their
medical record revealed conditions that would
interfere with their ability to participate in the
study, such as terminal illness, dementia, and
severe functional impairment.  Finally, patients
were excluded if evidence of hypertension-related
target organ damage was present (documentation
of retinopathy, renal changes such as serum
creatinine level > 2.0 mg/dl or albuminuria,
chronic heart failure, stroke, peripheral arterial
disease, and ischemic heart disease with a history
of myocardial infarction, percutaneous coronary
revascularization procedure, or coronary artery
bypass graft surgery).  Documentation of left
ventricular hypertrophy in the medical record
was an exclusion criteria.  However, left ventricular
hypertrophy was not universally assessed and
could not be ruled out for all patients in the
study.  The study was reviewed and approved by
the institutional review board of the university,
and written informed consent was obtained from
all patients.
Data Collection and Measures
Data were collected by self-administered
questionnaires mailed to patients’ homes.  A
follow-up reminder postcard was sent to
nonrespondents 2 weeks after the initial survey
packet was sent; those who still did not respond
received a second survey packet 1 month after
the mailing of the first survey.  Telephone follow-
up was attempted for nonrespondents, but few
patients were accessible during normal business
hours.
Symptoms were identified using a modification
of the Symptom Distress Checklist (SDC), a
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questionnaire developed for use in clinical trials
to identify the existence of symptoms related to
hypertension and antihypertensive drug adverse
effects and the impact they have on patients.14–16
The SDC used for this study consisted of a list of
51 symptoms.  We added an item related to
sexual dysfunction.  The questionnaire asks
whether the patient experienced the symptom
during the past 4 weeks (yes or no), the
frequency of the problem in the past 4 weeks,
and the extent to which it caused distress.  For
each symptom the patient documents as being
present, the patient completes two additional
questions to characterize the symptom.  First, the
patient indicates how frequently the symptom
occurs by choosing one of four response options
ranging from “once or twice” over the 4 weeks
(assigned a value of 1) to “daily or more often”
(assigned a value of 4).  Next, the patient
indicates the amount of distress the symptom
caused during the past 4 weeks.  There are five
response options to quantify the distress caused
by each symptom.  If the patient indicates that a
symptom caused minimal or no distress, the
symptom is assigned a value of zero.  The other
end of the distress scale—extreme distress—has a
value of 4.  A symptom distress level then can be
calculated for each documented symptom by
multiplying the value assigned to the response
for frequency of occurrence times the value
assigned to the distress it causes.  For example, if
the symptom occurred twice/week (assigned a
value of 2) and caused a moderate amount of
distress (assigned a value of 3), the symptom
distress level for that symptom is 6.
Two summary measures were calculated from
the SDC symptoms.  The first was the number of
symptoms reported/patient (SDC count, range
0–51).  The second was the overall distress level
of reported symptoms (overall symptom distress
[OSD]).  The OSD equals the sum of individually
reported symptom distress levels.  For example, a
patient who experienced three symptoms with
distress levels of 6, 12, and 16 would have an
OSD of 34.  The range for the OSD score is 0–816.
The Short Form-36 (SF-36) Health Survey,
version 1.0 (The Health Institute, New England
Medical Center, Boston, MA)17 was used to assess
HRQOL.  The SF-36 is a validated 36-item
questionnaire that measures the health concepts
of physical functioning, role limitations due to
physical health problems, bodily pain, general
health, vitality, social function, role limitations
due to emotional problems, and mental health.  It
also contains a single item that examines change
in health over time.  Summary measures of
physical health (Physical Component Summary
[PCS]) and mental health (Mental Component
Summary [MCS]) are derived from the completed
questionnaire.  The PCS and MCS were used for
this analysis.  Item scores are coded, summed,
and transformed to a scale ranging from 0 (worst
health status) to 100 (best health status), then
adjusted to norm-based scaling for final scores
for PCS and MCS.  The questionnaire uses a 4-
week recall period.  A scantron version of the SF-
36 was used (Response Healthcare Information
Management, Inc., East Greenwich, RI).
Patient-related data obtained from the self-
administered questionnaire included age, sex,
race, income, education level, and self-reported
length since diagnosis of hypertension.
Information also was collected on prescribed
drugs, including drug name, dose, and frequency,
as well as length of current therapy.  The medical
record was used to confirm age, sex, and race.
Disease characteristics such as blood pressures,
other documented diseases, and prescribed
antihypertensive drugs were obtained from the
medical record.  Self-reported treatment information
matched that found in the medical record for all
patients.  All systolic and diastolic blood pressures
documented in the medical record in the year
preceding the study were recorded.  The most
recent blood pressure recorded in the medical
record was used for analysis.  Although a statis-
tically significant difference (p=0.01) existed
between mean 1-year systolic blood pressure
(143.7 mm Hg) and most recent systolic blood
pressure (104.3 mm Hg), we felt that the relative
difference between the values was insignificant.
Data obtained from the medical record were used
in part for a nonresponse bias assessment.
Data Analysis
Descriptive data are presented as mean ± SD or
frequency (%).  Multivariable linear regression
was used to determine the relationship of
symptom data to PCS and MCS.  Patient, disease,
and treatment variables were added first to the
model, followed by one of the SDC summary
variables (SDC count or OSD).  The final
regression model was developed through
stepwise elimination of variables that lacked
statistical significance (p>0.05).  Separate models
were run for each SDC summary variable (SDC
count and OSD) and each SF-36 variable (PCS
and MCS).
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Results
The inclusion criteria were met by 222 patients.
Two questionnaire packets were undeliverable,
leaving a sample of 220 patients.  A total of 125
patients responded to the survey for a 56.8%
response rate.
Nonresponse bias assessment showed no
differences between respondents and nonrespon-
dents based on blood pressure, sex, or number of
prescribed antihypertensive entities.  However,
more patients over 65 years of age responded
(58.9% respondents vs 55.5% nonrespondents,
p=0.03) whereas fewer African-American patients
responded (17.1% respondents vs 35.8%
nonrespondents, p=0.005).
Patient characteristics are listed in Table 1.
There was a fairly equal distribution with regard
to sex and income.  There were more Caucasian
than minority patients.  Patients tended to have
had the disease for many years and had relatively
stable drug regimens.  The drug classes most
commonly reported were diuretics (33.3%),
followed by angiotensin-converting enzyme
inhibitors (20.6%), b-blockers (18.4%), and
calcium channel blockers (15.8%).  Other drugs
were peripheral a-blockers (terazosin and
prazosin), centrally acting agents (clonidine and
methyldopa), and direct-acting agents (minoxidil).
Patients took an average of one to two antihyper-
tensive drugs.
Nearly all respondents (122 of 125 [97.5%])
indicated that they experienced at least one
symptom.  The mean number of reported
symptoms (SDC count) was 8.8 ± 7.8 (range
0–35).  The mean OSD was 31.6 ± 46.2 (range
0–261).  Symptoms reported by more than 30%
of patients were lethargy, fatigue, tiredness,
lightheadedness, nocturia, dryness of mouth, and
heartburn.  The mean PCS was 48.7 ± 9.3 (range
21.9–63.1).  The mean MCS was 51.6 ± 10.1
(range 16.6–67.0).
The results of final regression models for the
relationships between number of reported
symptoms (SDC count); characteristics of the
patient, disease, and treatment; and HRQOL
(PCS and MCS) are presented in Table 2.  Age,
length of current drug therapy, and SDC count all
had negative influences on the physical-related
HRQOL score (PCS), with older age, longer
therapy, and greater number of reported
symptoms being associated with lower scores.
The SDC count had the strongest relationship
with the PCS score of all variables evaluated.  For
the MCS model, sex and SDC count were the
only variables.  Women reported more symptoms
and had lower mental-related HRQOL (MCS)
scores than men.  The SDC count variable had an
even stronger relationship with MCS score than
did sex.  The explained variance in the final SDC
count models was 0.31 and 0.41 for the PCS and
MCS models, respectively.
The results of regression models demonstrating
the relationship between OSD and HRQOL are
shown in Table 3.  The final PCS model retained
the length of current therapy, systolic blood
pressure, and OSD.  Lower PCS scores were
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Table 1.  Characteristics of the 125 Respondents
Characteristic Value
Mean ± SD
Age (yrs) 59.0 ± 11.2
Most recent blood pressure (mm Hg)
Systolic 139.6 ± 20.7
Diastolic 85.5 ± 11.8
Duration of hypertension diagnosis (yrs) 16.5 ± 12.2
Duration of current antihypertensive
drug regimen (yrs) 3.8 ± 4.6
No. of hypertensive drugs 1.5 ± 0.7
No. (%)
Sex
Male 59 (47.2)
Female 66 (52.8)
Racea
Caucasian 91 (75.2)
African-American 22 (18.2)
Other 8 (6.6)
Yearly household income ($)b
< 20,000 12 (10.7)
20,000–39,999 17 (15.2)
40,000–59,999 32 (28.6)
60,000–79,999 20 (17.9)
‡ 80,000 31 (27.7)
aOnly 121 responded.
bOnly 112 responded.
Table 2.  Standardized Regression Coefficients for Final
Models Relating Symptom Count (SDC Count) to Health-
Related Quality of Life
Variable PCS MCS
Adjusted R2 0.31 0.41
Age -0.28a
Sex -0.15b
Duration of current therapy -0.21c
No. of symptoms reported -0.51d -0.62d
(SDC count)
PCS = SF-36 Physical Component Scale; MCS = SF-36 Mental
Component Scale; SDC = Symptom Distress Checklist.
ap=0.001.
bp=0.03
cp=0.01.
dp<0.001.
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associated with longer duration of current
therapy, higher systolic pressure, and more
symptom-related distress.  The OSD variable had
a stronger relationship to PCS than did the length
of therapy or the systolic blood pressure
variables.  The final MCS model included a
number of patient and disease variables,
including age (older age, better MCS score), sex
(women had lower MCS scores), systolic blood
pressure (patients with higher systolic blood
pressures had lower MCS scores), and OSD.
Younger patients, women, patients with higher
systolic blood pressures, and patients reporting
greater total symptom distress had lower MCS
scores than other categories of patients.  The
OSD variable demonstrated the greatest
relationship to the MCS score.  The explained
variance in the final OSD models was 0.22 and
0.40 for the final PCS and the MCS models,
respectively.
Discussion
The presence of symptoms, regardless of their
source, may influence the HRQOL of patients
receiving drug therapy for hypertension.  A
previously published model13 provided a useful
framework for demonstrating the relationship
between symptoms and HRQOL.  When we
controlled for patient, disease, and treatment
characteristics, the summary symptom measures
emerged as the strongest predictors of both
physical and mental HRQOL measures.  The
source of symptoms may derive from the illness
(elevated blood pressure) or from adverse effects
of treatment.  Moreover, some symptoms may
have no identifiable cause, such as somatoform
symptoms common in the general population.
Other studies have reached similar conclusions;
that is, they have shown a strong association
between symptoms and HRQOL in patients
receiving treatment for hypertension.18, 19 Our
findings are consistent with and help justify the
previously published causal model,13 in which
symptoms mediate effects between root causes,
such as disease or drugs, and HRQOL.
Symptoms in the patient receiving treatment
for hypertension may have many causes.
Although often regarded as an asymptomatic
illness, hypertension has been associated with
headache, blurred vision, nocturia, unsteadiness,
dizziness, sexual problems, cognitive impairment,
and tiredness.20–26 Many symptoms reported by
patients with hypertension are similar to
nonspecific symptoms seen in the general clinic
population.27, 28 To compound the issue, most
antihypertensive drug therapies are associated
with adverse effects that are similar to commonly
reported symptoms in primary care.8, 29
In a recent study, patients experiencing drug-
related side effects in association with their
treatment for hypertension reported the lowest
assigned value for HRQOL, using utility analysis,
of all patients in the study.30 Other studies have
documented that antihypertensive drugs do cause
troublesome adverse effects that may affect
HRQOL to various degrees, depending on the
specific agent.31–33 An interesting observation is
that systolic blood pressure was related to both
the PCS and MCS HRQOL scores in their
respective models using OSD but not for the
symptom frequency models.  Other research also
has demonstrated an influence of blood pressure
on HRQOL.1 However, the presence of an
increasing number of symptoms as well as
distress associated with the symptoms have an
overall greater effect on HRQOL than blood
pressure.
Previous research has demonstrated that
patients with hypertension have lower HRQOL
than the general population.34 The Medical
Outcomes Study found lower general health
perception in patients with hypertension than in
patients without chronic conditions.19 The
investigators postulated that most variance in
functioning and well-being (HRQOL) was not
explained by the presence of a chronic condition
such as hypertension; rather, they suggested that
other variables, such as severity and duration of
the condition, type of treatment provided, style
of medical care (reassurance or information), and
other patient characteristics (exercise habits,
weight, or will to function) influenced perceived
348
Table 3.  Standardized Regression Coefficients for Final
Models Relating Overall Symptom Distress (OSD) to
Health-Related Quality of Life
Variable PCS MCS
Adjusted R2 0.22 0.40
Age 0.18a
Sex -0.22b
Systolic blood pressure -0.22c -0.21d
Duration of current therapy -0.28b
Overall symptom distress -0.41e -0.55e
PCS = SF-36 Physical Component Scale; MCS = SF-36 Mental
Component Scale.
ap=0.04.
bp=0.01.
cp=0.03.
dp=0.02.
ep<0.001.
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outcomes.  Other research has suggested similar
hypotheses.34 Our study adds to this literature by
suggesting that a significant proportion of
HRQOL variance can be explained by patients’
symptoms, regardless of root cause.
Patient drug-taking behavior may be influenced
by both the presence of symptoms, particularly
distressful symptoms, and changes in level of
functioning.  Patients may decide that a therapy
is not indicated if they perceive it to be the cause
of symptoms.35 There is evidence that lack of
motivation to take a treatment often arises from
mistaken beliefs about the necessity of the
treatment or from concerns about potential
adverse effects.36, 37 Often, these beliefs are
influenced by perceived symptoms.38 This is
particularly an issue with hypertension, an illness
that commonly is perceived by patients and
health care providers as asymptomatic.  Patient
decisions often reflect perceptions that may be
inappropriately linked to symptoms or changes
in functioning.39, 40
Symptom monitoring and management are
central to the improvement of patients’ HRQOL.
Our study provides evidence for a model that
links patients’ status with regard to biology,
symptoms, and functionality (HRQOL) and may
prove useful in guiding follow-up of patients who
receive treatment for hypertension.  The study
also provides evidence that patients often have
multiple symptoms that cause distress.  By
learning to identify symptoms and changes in
functioning, clinicians can increase their
effectiveness in helping patients maintain
adherent behavior with drug and nondrug
interventions in chronic diseases such as
hypertension.  Periodic administration of a
symptom and/or functional status (HRQOL)
questionnaire may be one method for identifying
issues that are not discussed during a normal
clinic visit.  Limited time and resources can make
it difficult to administer functional status
questionnaires or interpret symptoms during
office visits.  However, advancing computer and
personal device technologies soon may make
these interventions feasible.
The cross-sectional design of our study enabled
us to explore the relationship between symptoms
and HRQOL, but it did not allow us to directly
determine cause and effect.  For this, a more
sophisticated study design using longitudinal
data collection and larger numbers of patients is
necessary.  Another limitation of our study is that
study patients did not have other, more
symptomatic illnesses that may impair HRQOL.
Examples of highly symptomatic illnesses that
are often comorbidities with hypertension are
diabetes, ischemic heart disease, and other
conditions associated with hypertension-related
end-organ damage.  However, our study does
provide clinicians and researchers with evidence
of an association between symptoms and HRQOL
as measured by the SF-36.
Conclusion
Symptoms have a greater impact on SF-36
physical-related and mental-related scores than
patient characteristics, blood pressure, or drug-
related factors.  Clinicians should be aware that
detailed understanding of patients’ symptoms,
perhaps measured through available instruments,
may provide important insights that can help
assess and improve patients’ HRQOL.
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